A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents

Yih Wen Chen, James E. Cleaver, Fumio Hanaoka, Ching Fang Chang, Kai Ming Chou

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Genetic defects in polymerase η (pol η; hRad30a gene) result in xeroderma pigmentosum variant syndrome (XP-V), and XP-V patients are sensitive to sunlight and highly prone to cancer development. Here, we show that pol η plays a significant role in modulating cellular sensitivity to DNA-targeting anticancer agents. When compared with normal human fibroblast cells, pol η-deficient cells derived from XP-V patients were 3-fold more sensitive to β-D-arabinofuranosylcytosine, gemcitabine, or cis-diamminedichloroplatinum (cisplatin) single-agent treatments and at least 10-fold more sensitive to the gemcitabine/cisplatin combination treatment, a commonly used clinical regimen for treating a wide spectrum of cancers. Cellular and biochemical analyses strongly suggested that the higher sensitivity of XP-V cells to these agents was due to the inability of pol η-deficient cells to help resume the DNA replication process paused by the gemcitabine/cisplatin-introduced DNA lesions. These results indicated that pol η can play an important role in determining the cellular sensitivity to therapeutic agents. The findings not only illuminate pol η as a potential pharmacologic target for developing new anticancer agents but also provide new directions for improving future chemotherapy regimen design considering the use of nucleoside analogues and cisplatin derivatives.

Original languageEnglish (US)
Pages (from-to)257-265
Number of pages9
JournalMolecular Cancer Research
Volume4
Issue number4
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

gemcitabine
DNA-Directed DNA Polymerase
Cisplatin
Antineoplastic Agents
pol Genes
Sunlight
DNA
Cytarabine
DNA Replication
Nucleosides
Neoplasms
Therapeutics
Fibroblasts
Drug Therapy
Variant type Xeroderma pigmentosum

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research

Cite this

A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents. / Chen, Yih Wen; Cleaver, James E.; Hanaoka, Fumio; Chang, Ching Fang; Chou, Kai Ming.

In: Molecular Cancer Research, Vol. 4, No. 4, 04.2006, p. 257-265.

Research output: Contribution to journalArticle

Chen, Yih Wen ; Cleaver, James E. ; Hanaoka, Fumio ; Chang, Ching Fang ; Chou, Kai Ming. / A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents. In: Molecular Cancer Research. 2006 ; Vol. 4, No. 4. pp. 257-265.
@article{b54aeee461aa47b589b9e3b193356ede,
title = "A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents",
abstract = "Genetic defects in polymerase η (pol η; hRad30a gene) result in xeroderma pigmentosum variant syndrome (XP-V), and XP-V patients are sensitive to sunlight and highly prone to cancer development. Here, we show that pol η plays a significant role in modulating cellular sensitivity to DNA-targeting anticancer agents. When compared with normal human fibroblast cells, pol η-deficient cells derived from XP-V patients were 3-fold more sensitive to β-D-arabinofuranosylcytosine, gemcitabine, or cis-diamminedichloroplatinum (cisplatin) single-agent treatments and at least 10-fold more sensitive to the gemcitabine/cisplatin combination treatment, a commonly used clinical regimen for treating a wide spectrum of cancers. Cellular and biochemical analyses strongly suggested that the higher sensitivity of XP-V cells to these agents was due to the inability of pol η-deficient cells to help resume the DNA replication process paused by the gemcitabine/cisplatin-introduced DNA lesions. These results indicated that pol η can play an important role in determining the cellular sensitivity to therapeutic agents. The findings not only illuminate pol η as a potential pharmacologic target for developing new anticancer agents but also provide new directions for improving future chemotherapy regimen design considering the use of nucleoside analogues and cisplatin derivatives.",
author = "Chen, {Yih Wen} and Cleaver, {James E.} and Fumio Hanaoka and Chang, {Ching Fang} and Chou, {Kai Ming}",
year = "2006",
month = "4",
doi = "10.1158/1541-7786.MCR-05-0118",
language = "English (US)",
volume = "4",
pages = "257--265",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - A novel role of DNA polymerase η in modulating cellular sensitivity to chemotherapeutic agents

AU - Chen, Yih Wen

AU - Cleaver, James E.

AU - Hanaoka, Fumio

AU - Chang, Ching Fang

AU - Chou, Kai Ming

PY - 2006/4

Y1 - 2006/4

N2 - Genetic defects in polymerase η (pol η; hRad30a gene) result in xeroderma pigmentosum variant syndrome (XP-V), and XP-V patients are sensitive to sunlight and highly prone to cancer development. Here, we show that pol η plays a significant role in modulating cellular sensitivity to DNA-targeting anticancer agents. When compared with normal human fibroblast cells, pol η-deficient cells derived from XP-V patients were 3-fold more sensitive to β-D-arabinofuranosylcytosine, gemcitabine, or cis-diamminedichloroplatinum (cisplatin) single-agent treatments and at least 10-fold more sensitive to the gemcitabine/cisplatin combination treatment, a commonly used clinical regimen for treating a wide spectrum of cancers. Cellular and biochemical analyses strongly suggested that the higher sensitivity of XP-V cells to these agents was due to the inability of pol η-deficient cells to help resume the DNA replication process paused by the gemcitabine/cisplatin-introduced DNA lesions. These results indicated that pol η can play an important role in determining the cellular sensitivity to therapeutic agents. The findings not only illuminate pol η as a potential pharmacologic target for developing new anticancer agents but also provide new directions for improving future chemotherapy regimen design considering the use of nucleoside analogues and cisplatin derivatives.

AB - Genetic defects in polymerase η (pol η; hRad30a gene) result in xeroderma pigmentosum variant syndrome (XP-V), and XP-V patients are sensitive to sunlight and highly prone to cancer development. Here, we show that pol η plays a significant role in modulating cellular sensitivity to DNA-targeting anticancer agents. When compared with normal human fibroblast cells, pol η-deficient cells derived from XP-V patients were 3-fold more sensitive to β-D-arabinofuranosylcytosine, gemcitabine, or cis-diamminedichloroplatinum (cisplatin) single-agent treatments and at least 10-fold more sensitive to the gemcitabine/cisplatin combination treatment, a commonly used clinical regimen for treating a wide spectrum of cancers. Cellular and biochemical analyses strongly suggested that the higher sensitivity of XP-V cells to these agents was due to the inability of pol η-deficient cells to help resume the DNA replication process paused by the gemcitabine/cisplatin-introduced DNA lesions. These results indicated that pol η can play an important role in determining the cellular sensitivity to therapeutic agents. The findings not only illuminate pol η as a potential pharmacologic target for developing new anticancer agents but also provide new directions for improving future chemotherapy regimen design considering the use of nucleoside analogues and cisplatin derivatives.

UR - http://www.scopus.com/inward/record.url?scp=33646158472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646158472&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-05-0118

DO - 10.1158/1541-7786.MCR-05-0118

M3 - Article

VL - 4

SP - 257

EP - 265

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -